Loomis, Sayles & Company’s AngioDynamics ANGO Stock Holding History
Bought
Maintained
Sold
Other funds holding ANGO
SFM
Loomis, Sayles & Company's ANGO Position: Q4 2022 in Review
Loomis, Sayles & Company sold out of AngioDynamics (ANGO) in Q4 2022, closing a stake of 1,387,568 shares — an estimated $28.4M sold.
Loomis, Sayles & Company first reported a position in ANGO in Q4 2016 and held it in 17 quarters. The position peaked at $28.4M in Q3 2022. 149 funds tracked by Wall St. Rank hold ANGO as of Q4 2022.
- Loomis, Sayles & Company reported no remaining AngioDynamics position as of Q4 2022 after selling out during the quarter.
- Loomis, Sayles & Company sold 1,387,568 AngioDynamics shares in Q4 2022, an estimated $28.4M.
- Loomis, Sayles & Company first reported a position in AngioDynamics in Q4 2016 and held it in 17 quarters.
- Loomis, Sayles & Company's AngioDynamics position peaked at $28.4M in Q3 2022.
- 149 funds tracked by Wall St. Rank held AngioDynamics as of Q4 2022.
Based on Loomis, Sayles & Company's 13F filing for Q4 2022, filed 10 Feb 2023.